Clients News • MC Services corporate website
paged,page-template-default,page,page-id-5522,paged-10,page-paged-10,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.5.0,vc_responsive




  • CatalYm GmbH: CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer
  • Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
  • Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao
  • Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients
  • Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM
  • Secarna Pharmaceuticals: Data published in Molecular Diagnostics & Therapy demonstrate how Secarna’s powerful bioinformatics generate improved LNA-modified antisense oligonucleotide therapies
  • Atriva Therapeutics Announces Changes to Advisory Board
  • Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
  • XPHYTO announces business strategy and milestones for 2021: Innovation to impact
  • ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy